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COST-EFFECTIVENESS ANALYSIS OF ADALIMUMAB VS. 
CERTOLIZUMAB MAINTENANCE THERAPIES FOR MODERATE TO 
SEVERE CROHN’S DISEASE
Johnson S1, Kaltenboeck A1, Horn C1, Mulani P2, Majethia S2, Chao J2
1Analysis Group, Inc., Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: To examine the cost effectiveness (CE) of certolizumab vs. adalimumab
for Crohn’s disease. METHODS: CE was modeled as a function of time in remission; 
hospitalizations; dosing; biologic and medical costs; and QALYs. Certolizumab 
model inputs were imputed/estimated from PRECISE 1/2. Adalimumab inputs 
came from the every-other-week (eow) and placebo arms of CHARM. Adalimumab 
and certolizumab baseline characteristics were matched based on sex, prior anti-
TNF history, and CDAI. Remission, hospitalizations, and dosage were weighted 
based on matching. Two comparisons were made: Base Case Model (BCM) 1: adalim-
umab vs. certolizumab; and BCM2: treatment minus placebo. Hospitalization costs, 
other medical costs, and utility were derived the literature. Drug costs were based on 
2008 WAC. Since no data were available for certolizumab effects on hospitalization, 
data were imputed from a regression model employing CHARM data. Data were ana-
lyzed in a cost-utility framework from a payer perspective. RESULTS: In BCM1, 
adalimumab patients accrued greater expected incremental health utility (0.0072) in 
the ﬁ rst 26 weeks of therapy vs. certolizumab. The average 26-week remission rates
were 37.4% for adalimumab and 24.4% for certolizumab. Drug-related costs for cer-
tolizumab totaled $9110, while hospitalization costs and other direct medical costs
were $2943 and $6,523. Adalimumab drug-related costs totaled $7704, while hospi-
talization costs and other direct medical costs were $2224 and $6015. In BCM2, dif-
ference in health utility between 1) certolizumab and placebo was 0.0027, and 2)
adalimumab and placebo was 0.0066 (adalimumab advantage of 0.0039). The 26-
week average NNTs were 6.7 for adalimumab and 14.4 for certolizumab. In BCM1
(vs. PRECISE 2), adalimumab patients were $456 less costly and incurred 0.0061 
greater incremental health utility. In BCM2, adalimumab had a 0.0041 incremental 
advantage. The 26-week average NNTs were 7.02 for adalimumab and 15.96 for 
certolizumab. CONCLUSIONS: These results suggest adalimumab eow maintenance
therapy is a dominant strategy vs. certolizumab.
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COST-EFFECTIVENESS OF PEG-IFN ALPHA 2A OR 2B PLUS RIBAVIRIN
IN THE TREATMENT OF CHRONIC HEPATITIS C IN MEXICO
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OBJECTIVES: To compare the cost-effectiveness of peginterferon alpha 2a or alpha
2b, plus ribavirin, in the treatment of Hepatitis C virus chronic infection, from an 
institutional perspective, in the Mexican setting. METHODS: Using a decision tree, a
Hepatitis C virus chronic infection 1-year treatment was modeled. The effectiveness
of each treatment against genotypes 1, 2, or 3 was obtained using a previously pub-
lished meta-analysis; the effectiveness measure was the percentage of patients who 
obtained a sustained viral response. Epidemiological data were included for genotype
population distributions in Mexico. The utilized health care resources were derived
from the Hepatitis C National Consensus and records from a reference hospital,
whereas costs were obtained from purchasing records from a public institution. Costs 
were estimated using prices of 2008 and are expressed in US dollars (exchange rate
of 11.14 pesos/ 1 US dollar). RESULTS: The cost for drugs accounted for over 80% 
of total treatment cost. Average costs per patient treated were: $8422.16 for pegin-
terferon alpha 2b  ribavirin vs. $9452.59 for peginterferon alpha 2a  ribavirin. 
Effectiveness achieved in obtaining a case with sustained viral response for peginter-
feron alpha 2b  ribavirin was 12% higher compared to peginterferon alpha 2a 
ribavirin. Average cost–effectiveness ratios corresponding to cost per patient with
sustained viral response were $14,921.42 for peginterferon alpha 2b  ribavirin: and
$21,221.53 for peginterferon alpha 2a  ribavirin. Incremental cost–effectiveness 
ratios obtained in the model show peginterferon alpha 2b  ribavirin treatment as the 
most cost–effective or dominant strategy, since using peginterferon alpha 2a  ribavirin 
has a cost of $8658.28 pesos for an additional patient to present sustained viral 
response. CONCLUSIONS: Ribavirin plus peginterferon alpha 2b combination was 
the most cost-effective treatment, in the Mexican context, according to the proposed
decision tree model.
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ECONOMIC ANALYSIS OF THE POTENTIAL USAGES OF ALVIMOPAN
AND METHYLNALTREXONE AT A TERTIARY CANCER CENTER
Lal LS1, Xu R2, Smith WD1, Miller LA3, Arbuckle R1
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OBJECTIVES: One of the major mandates of the Formulary Management System
(FMS) is to evaluate and select drugs using the highest level of evidence available, 
including cost-effectiveness and budget impact. The purpose of this study is to
provide pharmacoeconomic analysis for P&T Committee from the institutional per-
spective for alvimopan and methylnaltrexone, two peripheral opioid antagonists
recently approved by FDA. METHODS: A decision analysis model was developed
for alvimopan vs. both placebo and chewing gum, using time to hospital discharge
as the primary outcome. For methylnaltrexone, the decision analysis compared to
placebo determined the probability of laxation as the primary outcome. Institutional 
acquisition costs were utilized for the analysis. A budget impact analysis of both 
products was also conducted. RESULTS: Alvimopan has incremental cost-effectiveness 
ratio (ICER) of $51 per hour of reduced LOS vs. placebo, and an ICER of $81 
per hour of longer LOS vs. chewing gum. Methylnaltrexone has an ICER of $636 
per probable bowel movement, the approved FDA indication, compared with
placebo. The estimated annual budget impact of alvimopan and methylnaltrexone 
on MDACC is $375,000 and $134,400, respectively. CONCLUSIONS: In summary,
alvimopan is more effective and more costly than placebo for postoperative ileum. 
However, alvimopan is less effective and most costly than chewing gum for the same 
indication. The other peripheral opioid antagonist methylnaltrexone is more effective 
and more costly than placebo for opioid-induced constipation. Though a very basic 
model, the decision analysis model provided another layer to the ﬁ nal decision 
process.
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BURDEN OF SURGICALLY RESECTED GASTROINTESTINAL STROMAL 
TUMORS (GIST) IN THE US
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OBJECTIVES: Adjuvant therapy for patients with surgically resected GIST leads to a 
signiﬁ cant reduction in recurrence. The purpose of this study was to evaluate costs
and outcomes associated with surgically resected localized GIST (SRLG) and recurrent 
GIST. METHODS: We conducted a retrospective analysis of the Surveillance, Epide-
miology, and End Results (SEER)-Medicare linked database, containing information 
from the SEER cancer registry linked to administrative claims from Medicare. Patients 
with a diagnosis of GIST from 1993–2002 were identiﬁ ed using a combination of 
primary cancer site and ICD-O-2 histology codes typical for GIST, and the ICD-O-3 
GIST code, where available. Patients with SRLG were retained and their Medicare 
claims scanned from the time of GIST diagnosis through 2005 to assess survival and
health care costs. All GIST patients were age and sex matched 1:1 to GIST free con-
trols; patients with recurrence were matched to recurrence-free controls for recurrence 
analyses. GIST- and recurrence-attributable costs were estimated using the Kaplan-
Meier Sample Average method using up to 10-years of follow-up data and computing 
the difference between cases and controls. RESULTS: We identiﬁ ed 292 patients in
the SEER-Medicare data with SRLG; 35 with recurrence. Median overall survival was 
59 months among all GIST patients, and recurrence-free survival was 45 months. 
Median post-recurrence survival was 46 months. Recurrence-free survival was 82%, 
69%, and 39% at 1, 2, and 5 years respectively. Per-patient costs ($2005 US) attribut-
able to SRLG were ~$19,500 (95% CI $3,700, $37,500) with the majority of costs 
incurred in the ﬁ rst 3 years after diagnosis; the associated annual burden was estimated 
to be ~$33.1 million among ~4,100 prevalent cases. Per-patient costs attributable to 
GIST recurrence were ~$97,900 (95% CI $28,200, $197,500). CONCLUSIONS:
GIST recurrence is associated with poor survival and increased medical-care costs. 
Adjuvant treatments that delay or eliminate recurrence could substantially reduce the
burden of GIST.
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OBJECTIVES: Anti-TNF-alpha agents for Crohn’s disease (CD) have good clinical
efﬁ cacy but high acquisition cost compared to rival drugs. Previous modelling esti-
mates are limited by a lack of primary data for costs of care and health state utility. 
The aim of the present study was to undertake an independent analysis incorporating
data from recent trials and observational studies from the perspective of the UK 
National Health Service. METHODS: Lifetime Markov analyses constructed to simu-
late outcomes and costs. CD was represented by 5 disease states: Full Response (CDAI 
 150, remission); Partial Response (CDAI 150–220, mild-to-moderate activity); Non-
Response (CDAI  220, moderate-to-severe activity); Surgery and Death. The course 
of Crohn’s disease under standard care was modelled from a transition matrix derived
from the Olmsted county cohort. Systematic review identiﬁ ed ACCENT I (inﬂ iximab) 
and CHARM (adalimumab) as sources for efﬁ cacy data. We modelled an intention-
to-treat strategy for biologics by including a non-responder cohort (representing 
patients excluded from the trials after failed induction). Surgical rates were based on
observational data; cost estimates were taken from our UK dataset and utilities were
derived for each state from an algorithm converting CDAI to EQ-5D utilities. 
RESULTS: In the base-case analysis (lifetime horizon; 1–2 years continuous therapy; 
discount rate 3.5%) both agents achieved acceptable ICERs compared to standard
care (Inﬂ iximab: a19,050 [1 yr]; a21,300 [2 yrs]; Adalimumab: a7,190 [1 yr]; a10,310 
[2 yrs]). Lifetime therapy was dominated by standard care. Analyses over shorter time 
horizons, matched to treatment duration, resulted in unfavourable ICERs. CONCLU-
SIONS: Contrary to earlier analyses, the model suggests acceptable ICERs for bio-
logical agents when considering a lifetime horizon with periods of at least 4 years 
continuous therapy. Apparent differences between rival biological agents must be
interpreted cautiously as head-to-head trial data are not available.
